InvestorsHub Logo
Followers 0
Posts 3
Boards Moderated 0
Alias Born 12/30/2009

Re: None

Friday, 01/13/2017 8:39:42 PM

Friday, January 13, 2017 8:39:42 PM

Post# of 9136
most intriguing part of study 202 phase 2 is the OS of 11.9% for low HA with n=53. Appears peg works on all pancreatic cancer irregardless of HA status. This is great news as the addressable market for PEG is now potentially much larger for other solid cancers.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News